Abstract #4240

Comparison of gadoterate meglumine and gadobutrol in MRI diagnosis of brain tumors: a double-blind randomized intra-individually controlled in cross-over study (the REMIND study)

Kenneth Maravilla¹, Daniel San Juan Orta², Sang Joon Kim³, and Guillermo Elizondo Riojas⁴

¹Radiology, University of Washington, Seattle, WA, United States, ²Clinical Research Institute S.C., Tlanepantla de Baz, Mexico, ³Asan medical center / Radiology, Seoul, Korea, Democratic People's Republic of, ⁴Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Mexico

This double-blind randomized cross-over study was conducted to demonstrate non-inferiority of gadoterate meglumine vs. gadobutrol in MRI diagnosis of brain tumors. Images from two identical MRIs with each agent were evaluated by three independent off-site readers. Overall lesion visualization and characterization was scored as “good” or “excellent” in >90% of patients by all readers. Despite a small difference in signal intensity measurements in favor of gadobutrol, similar results were observed with the two agents regarding overall lesion visualization and characterization or qualitative efficacy criteria. Non-inferiority of gadoterate meglumine vs. gadobutrol in diagnosis of brain tumors by MRI was demonstrated.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.